FDA Revises Bioequivalence Evaluation Standards for Inhaled Generics, Expected to Accelerate Development of Viatris' 'Breyna'
Background of the Inhaled Generics Workshop
The U.S. Food and Drug Administration (FDA) and the Center for Research on Complex Generics (CRCG) will jointly host a public workshop from October 14-15, 2026, to innovate the bioequivalence (BE) evaluation system for inhaled drugs. This workshop is organized under the Third Generic Drug User Fee Act (GDUFA III) to enhance regulatory science research and reduce barriers to market entry for complex generics, which are more difficult to develop. With a global prevalence of 650 million asthma and chronic obstructive pulmonary disease (COPD) patients, the provision of affordable and effective generic drugs is essential for improving public health and reducing healthcare costs. The regulatory agency's proactive revision of guidelines indicates the urgent need for the rapid localization and provision of alternative therapies.
Innovation in Bioequivalence Evaluation Methods
Existing bioequivalence evaluations for inhaled drugs have relied on large-scale clinical endpoint trials involving patients, which are costly and have high variability in results. This workshop will focus on an option-based framework that organically integrates in vitro, in vivo, and in silico methods to overcome these limitations. In particular, computational fluid dynamics (CFD) modeling for predicting regional lung deposition is gaining attention for its ability to accurately simulate the complex drug distribution within the lungs. The introduction of these innovative non-clinical alternative testing methods is expected to significantly reduce clinical trial costs and the probability of approval failure.
Global Respiratory Market and Key Target Pipelines
The global market for asthma and COPD treatments is currently valued at approximately $44.7 billion to $92.3 billion (approximately 60 to 125 trillion KRW) per year, based on 2025-2026 figures, making it a massive market. Blockbuster originator drugs such as Symbicort (budesonide/formoterol) from AstraZeneca (AZN) and Advair (fluticasone/salmeterol) from GlaxoSmithKline (GSK) are representative targets for generic conversion. Viatris (VTRS) has partnered with Kindeva Drug Delivery to obtain approval for Breyna, a Symbicort generic, and Teva (TEVA), Hikma (HKMPY), and Cipla (CIPLA) are also actively developing complex formulations. Generic drug developers are fiercely competing to secure a share of the high-margin respiratory market due to the barriers to entry posed by complex formulations and drug delivery devices.
Impact on the Pharmaceutical and Biotechnology Industry and Investment Ecosystem
The FDA's modernization of the bioequivalence evaluation system is a significant factor in reducing the research and development (R&D) uncertainty for pharmaceutical companies with complex formulation pipelines. By utilizing regulatory-approved computer modeling and in vitro data packages instead of uncertain clinical trials, the risk of Complete Response Letters (CRLs) can be reduced. From the perspective of venture capital (VC) and institutional investors, the investment attractiveness of companies with device development capabilities or computational modeling platform technology is expected to increase significantly. As a result, the early resolution of the monopoly of innovative pharmaceutical companies is expected to intensify price competition in the market and accelerate the revenue growth of leading complex generic companies.
With the global asthma and COPD treatment market valued at approximately $44.7 billion to $92.3 billion, the enhancement of these guidelines is expected to accelerate generic entry by more than two years by replacing Phase 3 clinical trials. In the short term, companies such as Hikma (HKMPY) and Teva (TEVA) are expected to significantly reduce development costs by benchmarking Viatris' (VTRS) 'Breyna' approval pathway. From a researcher's perspective, computational fluid dynamics (CFD)-based in silico modeling is expected to be established as an official regulatory validation tool, leading to a surge in demand for related bio-simulation platforms. In the medium to long term, the rapid increase in the penetration rate of generics in the respiratory blockbuster market, which was previously dominated by monopolies, is expected to have a significant impact on the sales defense strategies of originator companies. As a result, the resolution of uncertainties in the approval of complex generics is expected to significantly activate venture capital (VC) investment in development pipelines with improved capital efficiency.